The Role of Therapeutic Plasma Exchange (TPE) in Multisystem Inflammatory Syndrome in Children (MIS-C)
Abstract
:1. Introduction
2. Materials and Methods
2.1. Data Collection
2.2. Statistical Analysis
2.3. Ethics Committee and Informed Consent
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-27-january-2021 (accessed on 27 January 2021).
- CDC Coronavirus Disease 2019 in Children—United States, 12 February–2 April 2020. Available online: https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e4.htm (accessed on 6 April 2020).
- Parri, N.; Lenge, M.; Buonsenso, D. Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group Children with Covid-19 in pediatric emergency departments in Italy. N. Engl. J. Med. 2020. [Google Scholar] [CrossRef]
- Tagarro, A.; Epalza, C.; Santos, M. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2020. [Google Scholar] [CrossRef] [Green Version]
- Royal College of Paediatrics and Child Health. Guidance: Paediatric Multisystem Inflammatory Syndrome Temporally Associated with COVID-19. 1 May 2020. Available online: https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf (accessed on 1 May 2020).
- CDC. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). 14 May 2020. Available online: https://emergency.cdc.gov/han/2020/han00432.asp (accessed on 1 May 2020).
- Jones, V.G.; Mills, M.; Suarez, D.; Hogan, C.A.; Yeh, D.; Segal, J.B.; Nguyen, E.L.; Barsh, G.R.; Maskatia, S.; Mathew, R. COVID-19 and Kawasaki disease: Novel virus and Novel Case. Hosp Pediatr. 2020, 10, 537–540. [Google Scholar] [CrossRef]
- WHO. Multisystem Inflammatory Syndrome in Children and Adolescents with Covid-19: Scientific Brief; World Health Organization: Geneva, Switzerland, 15 May 2020; Available online: https://apps.who.int/iris/handle/10665/332095 (accessed on 15 May 2020).
- Dufort, E.M.; Koumans, E.H.; Chow, E.J.; Rosenthal, E.M.; Muse, A.; Rowlands, J.; Barranco, M.A.; Maxted, A.M.; Rosenberg, E.S.; Easton, D.; et al. Multisystem Inflammatory Syndrome in Children in New York State. N. Engl. J. Med. 2020, 383, 347. [Google Scholar] [CrossRef]
- Verdoni, L.; Mazza, A.; Gervasoni, A.; Martelli, L.; Ruggeri, M.; Ciuffreda, M.; Bonanomi, E.; D’Antiga, L. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet 2020, 395, 1771. [Google Scholar] [CrossRef]
- Whittaker, E.; Bamford, A.; Kenny, J.; Kaforou, M.; Jones, C.E.; Shah, P.; Ramnarayan, P.; Fraisse, A.; Miller, O.; Davies, P.; et al. Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2. JAMA 2020, 324, 259–269. [Google Scholar] [CrossRef]
- Feldstein, L.R.; Rose, E.B.; Horwitz, S.M.; Collins, J.P.; Newhams, M.M.; Son, M.B.F.; Newburger, J.W.; Kleinman, L.C.; Heidemann, S.M.; Martin, A.A.; et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N. Engl. J. Med. 2020, 383, 334. [Google Scholar] [CrossRef] [PubMed]
- Godfred-Cato, S.; Bryant, B.; Leung, J.; Oster, M.E.; Conklin, L.; Abrams, J.; Roguski, K.; Wallace, B.; Prezzato, E.; Koumans, E.H.; et al. COVID-19-Associated Multisystem Inflammatory Syndrome in Children—United States, March–July 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1074. [Google Scholar] [CrossRef]
- Henderson, L.A.; Canna, S.W.; Friedman, K.G.; Gorelik, M.; Lapidus, S.K.; Bassiri, H.; Behrens, E.M.; Ferris, A.; Kernan, K.F.; Schulert, G.S.; et al. American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19: Version 2. Arthritis Rheumatol. 2020. [Google Scholar] [CrossRef]
- Belhadjer, Z.; Meot, M.; Bajolle, F. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020. [Google Scholar] [CrossRef]
- Hennon, T.R.; Penque, M.D.; Abdul-Aziz, R.; Alibrahim, O.S.; McGreevy, M.B.; Prout, A.J.; Schaefer, B.A.; Ambrusko, S.J.; Pastore, J.V.; Turkovich, S.J.; et al. COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; a Western New York approach. Prog. Pediatric Cardiol. 2020. [Google Scholar] [CrossRef]
- Atay, G.; Demirkol, D. Therapeutic Plasma Exchange Application in Children Requires Individual Decision. J. Pediatr. Intensiv. Care 2021, 10, 106–109. [Google Scholar] [CrossRef]
- Schwartz, J.; Padmanabhan, A.; Aqui, N.; Balogun, R.A.; Connelly-Smith, L.; Delaney, M.; Dunbar, N.M.; Witt, V.; Wu, Y.; Shaz, B.H. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: The seventh special issue. J. Clin. Apher. 2016, 31, 149–162. [Google Scholar] [CrossRef]
- Ahmed, M.; Advani, S.; Moreira, A.; Zoretic, S.; Martinez, J.; Chorath, K.; Acosta, S.; Naqvi, R.; Burmeister-Morton, F.; Burmeister, F.; et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine 2020, 26, 100527. [Google Scholar] [CrossRef]
- Chang, L.Y.; Lu, C.Y.; Shao, P.L.; Lee, P.I.; Lin, M.T.; Fan, T.Y.; Cheng, A.L.; Lee, W.L.; Hu, J.J.; Yeh, S.J.; et al. Viral infections associated with Kawasaki disease. J. Formos. Med. Assoc. 2014, 113, 148–154. [Google Scholar] [CrossRef] [Green Version]
- Hall, G.C.; Tulloh, L.E.; Tulloh, R.M. Kawasaki disease incidence in children and adolescents: An observational study in primary care. Br. J. Gen. Pract. 2016, 66, e271–e276. [Google Scholar] [CrossRef] [Green Version]
- Jiang, L.; Tang, K.; Levin, M.; Irfan, O.; Morris, S.K.; Wilson, K.; Klein, J.D.; Bhutta, Z.A. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect. Dis. 2020, 20, e276–e288. [Google Scholar] [CrossRef]
- Davies, P.; Evans, C.; Kanthimathinathan, H.K.; Lillie, J.; Brierley, J.; Waters, G.; Johnson, M.; Griffiths, B.; du Pré, P.; Mohammad, Z.; et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: A multicentre observational study. Lancet Child Adolesc. Health 2020, 4, 669–677. [Google Scholar] [CrossRef]
- Bustos, R.; Jaramillo-Bustamante, J.C.; Vasquez-Hoyos, P.; Cruces, P.; Díaz, F. Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2: A Case Series Quantitative Systematic Review. Pediatr. Emerg. Care 2021, 37, 44. [Google Scholar] [CrossRef] [PubMed]
- Keith, P.; Day, M.; Perkins, L.; Moyer, L.; Hewitt, K.; Wells, A. A novel treatment approach to the novel coronavirus: An argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit. Care 2020, 24, 128. [Google Scholar] [CrossRef] [Green Version]
- Zhang, L.; Zhai, H.; Ma, S.; Chen, J.; Gao, Y. Efficacy of therapeutic plasma exchange in severe COVID-19 patients. Br. J. Haematol. 2020, 190, 181–183. [Google Scholar] [CrossRef] [PubMed]
- Ye, Q.; Wang, B.; Mao, J. The pathogenesis and treatment of the Cytokine Storm’in COVID-19. J. Infect. 2020, 80, 607–613. [Google Scholar] [CrossRef]
- Khamis, F.; Al-Zakwani, İ.; Al-Hashmi, S.; Al Dowaiki, S.; Al Bahrani, M.; Pandak, N.; Al Khalili, H.; Memish, Z. Therapeutic plasma exchange in adults with severe COVID-19 infection. Int. J. Infect. Dis. 2020, 99, 214–218. [Google Scholar] [CrossRef] [PubMed]
- Demirkol, D.; Yildizdas, D.; Bayrakci, B.; Karapinar, B.; Kendirli, T.; Koroglu, T.F.; Dursun, O.; Erkek, N.; Gedik, H.; Citak, A.; et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: What is the treatment? Crit. Care 2012, 16, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Total patient number | 41 |
Age, years, median (interval) | 10(2–20) |
Gender, male, percentage (%) | 33(80.5) |
Weight, kilogram, median(interval) | 32(9–109) |
PICU admission, percentage (%) | 21(51,2) |
Duration of fever, day, median (interval) | 5(3–8) |
Concomitant chronic disease, percentage (%) | 8(19,5) |
Regular drug usage, percentage (%) | 6(14,63) |
History of covid positive case contact, percentage (%) | 18(43,9) |
Covid PCR positivity, percentage (%) | 2(%4,9) |
Covid Antibody positivity, percentage (%) | 37(%90,2) |
Clinical presentation | |
▪ Upper Respiratory Tract Findings, percentage (%) | 11(26,8) |
▪ Lover Respiratory Tract Findings, percentage (%) | 9(21,9) |
▪ Hematological Findings, percentage (%) | 1(2,4) |
▪ Central Nervous System Findings, percentage (%) | 5(12,2) |
▪ Gastrointestinal System Findings, percentage (%) | 19(46,3) |
▪ Cardiovascular System Findings, percentage (%) | 19(46,3) |
▪ Urinary System Findings, percentage (%) | 4(9,7) |
▪ Artralgia Findings, percentage (%) | 6(14,6) |
▪ Presence of lymphadenopathy, percentage (%) | 7(17,1) |
▪ Presence of conjuktivitis, percentage (%) | 11(26,8) |
PICU * Number of Inpatients | 21 |
Duration of hospitalization in PICU, day, median (range) | 5(1–75) |
Total duration of hospitalization, day, median (range) | 9(4–92) |
PRISM * score at the administiration of PICU, median (range) | 12(5–37) |
PELOD * score at the administiration of PICU, median (range) | 10(0–52) |
Number of patients on MV *, percentage (%) | 5(14,3) |
Number of patients applied TPE *, percentage (%) | 10(24,4) |
Number of patients applied ECMO *, percentage (%) | 3(8,6) |
Mortalite, percentage (%) | 2(5,7) |
Hospitalized in the PICU | Not Hospitalized in the PICU | p | |
---|---|---|---|
Age [mounth, median (range)] | 12(5–17) | 8(2–20) | 0.17 |
Duration of fever [day, median (range) | 5(3–8) | 5(3–8) | 0.629 |
Duration of hospitalization [day, median (range)] | 15(7–92) | 9(4–27) | 0.004 |
Gender [male, percentage] | 15(71,4) | 18(90) | 0.33 |
Laboratory parameters, median (range) | |||
Hematocrit (%) | 32(27–42) | 35.5(28–44) | 0.388 |
White blood cell count (cell/µL) | 8480(3680–31,340) | 10,880(1950–21,970) | 0.234 |
Absulute lymphocyte count (cell/µL) | 480(350–1200) | 1590(440–6320) | 0.001 |
Trombocyte count (cell/µL) | 195,000(69,000–423,000) | 314,500(97,000–715,000) | 0.011 |
C-reactive protein (mg/L) | 155(13–290) | 40(3–270) | 0.028 |
Eritrocyte sedimentation rate (mm/hr) | 36,5(14–92) | 45(7–63) | 0.695 |
Fibrinogen(g/L) | 607(113–907) | 525(290–859) | 0.869 |
Creatinin (mg/dL) | 1(0.5–1.2) | 1(0.4–1.1) | 0.952 |
Sodium(mmol/L) | 130(124–143) | 136(131–145) | 0.001 |
AST (U/L) | 33(14–162) | 29(14–69) | 0.621 |
ALT (U/L) | 30(7–92) | 19(9–68) | 0.028 |
GGT (U/L) | 51(6–248) | 18(7–45) | 0.129 |
LDH (U/L) | 323(172–1800) | 283(174–545) | 0.4 |
Ferritin (ng/ML) | 1200(367–22,627) | 332.5(16–3274) | 0.001 |
Triglyceride (mg/dL) | 180(96–383) | 121.5(41–239) | 0.129 |
Albumin (g/dL) | 3(2–4) | 4(3–5) | 0.001 |
PT | 17(12–25) | 16(13–20) | 0.316 |
aPTT | 32(28–42) | 29(26–40) | 0.952 |
D-dimer (mg/L) | 4400(1293–8400) | 1735(200–14,100) | 0.028 |
Pro-BNP | 790(165–7145) | 154(12–1135) | 0.04 |
Lactate | 3(1–21) | 1(1–4) | 0.005 |
Radiological Findings | |||
infiltration & pleural effusion in X-ray (%) | 4(23,5) | 0 | 0.07 |
Presence of the ecocardiography finding, (%) | 13(76,5) | 6(33,3) | 0.03 |
intraabdominal fluid in a ultrasoun (%) | 6(35,3) | 8(44,4) | 0.72 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Atay, G.; Hasbal, C.; Türk, M.; Erdoğan, S.; Sözeri, B. The Role of Therapeutic Plasma Exchange (TPE) in Multisystem Inflammatory Syndrome in Children (MIS-C). Children 2021, 8, 498. https://0-doi-org.brum.beds.ac.uk/10.3390/children8060498
Atay G, Hasbal C, Türk M, Erdoğan S, Sözeri B. The Role of Therapeutic Plasma Exchange (TPE) in Multisystem Inflammatory Syndrome in Children (MIS-C). Children. 2021; 8(6):498. https://0-doi-org.brum.beds.ac.uk/10.3390/children8060498
Chicago/Turabian StyleAtay, Gurkan, Canan Hasbal, Mücahit Türk, Seher Erdoğan, and Betül Sözeri. 2021. "The Role of Therapeutic Plasma Exchange (TPE) in Multisystem Inflammatory Syndrome in Children (MIS-C)" Children 8, no. 6: 498. https://0-doi-org.brum.beds.ac.uk/10.3390/children8060498